Insulet (PODD) Tops Q2 EPS by 21c

Insulet (NASDAQ: PODD) reported Q2 EPS of $1.66, $0.21 better than the analyst estimate of $1.45. Revenue for the quarter came in at $801.7 million versus the consensus estimate of $787.82 million.

Raises adjusted EPS growth guidance from >25% to >30%. Cuts FY revenue outlook growth from 21-23% to 20-22%.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• Gamma Resources raises private placement ceiling to $1.75M
• BiomX announces 1-for-10 reverse stock split effective Sept. 9